EMA's PRAC issues new safety information for healthcare professionals

11 June 2022

As part of its advice on safety-related aspects to European Medicines Agency committees stemming from its June 7-10 meetings, the Pharmacovigilance Risk Assessment Committee (PRAC) discussed direct healthcare professional communications (DHPCs) containing important information for Neofordex (dexamethasone) and Xalkori (crizotinib).

Xalkori: Vision disorders, including risk of severe visual loss, need for monitoring in pediatric patients

This DHPC informs healthcare professionals of the risk of ocular toxicity, severe visual loss and the need for monitoring in pediatric patients with Xalkori, marketed by US pharma giant Pfizer (NYSE: PFE).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK